{"doi":"10.1002/wnan.9","title":"Anti‐angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis","abstract":"<jats:title>Abstract</jats:title><jats:p>Complementary developments in nanotechnology, genomics, proteomics, molecular biology and imaging offer the potential for early, accurate diagnosis. Molecularly‐targeted diagnostic imaging agents will allow noninvasive phenotypic characterization of pathologies and, therefore, tailored treatment close to the onset. For atherosclerosis, this includes anti‐angiogenic therapy with specifically‐targeted drug delivery systems to arrest the development of plaques before they impinge upon the lumen. Additionally, monitoring the application and effects of this targeted therapy in a serial fashion will be important. This review covers the specific application of α<jats:sub>ν</jats:sub>β<jats:sub>3</jats:sub>‐targeted anti‐angiogenic perfluorocarbon nanoparticles in (1) the detection of molecular markers for atherosclerosis, (2) the immediate verification of drug delivery with image‐based prediction of therapy outcomes, and (3) the serial, noninvasive observation of therapeutic efficacy Copyright © 2009 John Wiley &amp; Sons, Inc.</jats:p><jats:p>This article is categorized under:\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Therapeutic Approaches and Drug Discovery &gt; Nanomedicine for Cardiovascular Disease</jats:p></jats:list-item>\n</jats:list></jats:p>","journal":"WIREs Nanomedicine and Nanobiotechnology","year":2009,"id":683016,"datarank":0.586803450814222,"base_score":3.912023005428146,"endowment":3.912023005428146,"self_citation_contribution":0.586803450814222,"citation_network_contribution":0.0,"self_endowment_contribution":0.586803450814222,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":49,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1784329,"name":"Tillmann Cyrus","orcid":null,"position":1,"is_corresponding":false},{"id":1784330,"name":"Patrick M. Winter","orcid":null,"position":2,"is_corresponding":false},{"id":372176,"name":"Samuel A. Wickline","orcid":"0000-0002-8949-3192","position":3,"is_corresponding":false},{"id":464853,"name":"Gregory M. Lanza","orcid":null,"position":4,"is_corresponding":false},{"id":1784328,"name":"Shelton D. Caruthers","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Anti‐angiogenic perfluorocarbon nanoparticles for diagnosis and treatment of atherosclerosis","abstract":"<jats:title>Abstract</jats:title><jats:p>Complementary developments in nanotechnology, genomics, proteomics, molecular biology and imaging offer the potential for early, accurate diagnosis. Molecularly‐targeted diagnostic imaging agents will allow noninvasive phenotypic characterization of pathologies and, therefore, tailored treatment close to the onset. For atherosclerosis, this includes anti‐angiogenic therapy with specifically‐targeted drug delivery systems to arrest the development of plaques before they impinge upon the lumen. Additionally, monitoring the application and effects of this targeted therapy in a serial fashion will be important. This review covers the specific application of α<jats:sub>ν</jats:sub>β<jats:sub>3</jats:sub>‐targeted anti‐angiogenic perfluorocarbon nanoparticles in (1) the detection of molecular markers for atherosclerosis, (2) the immediate verification of drug delivery with image‐based prediction of therapy outcomes, and (3) the serial, noninvasive observation of therapeutic efficacy Copyright © 2009 John Wiley &amp; Sons, Inc.</jats:p><jats:p>This article is categorized under:\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Therapeutic Approaches and Drug Discovery &gt; Nanomedicine for Cardiovascular Disease</jats:p></jats:list-item>\n</jats:list></jats:p>","is_dataset_classified":null,"base_score":3.912023005428146,"endowment":3.912023005428146,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"20049799","pmcid":null,"openalex_id":"https://openalex.org/W2049721678","authors":[],"funders":[],"total_grants":0,"fwci":4.6127,"citation_percentile":0.94498631,"influential_citations":0,"citation_trend":[{"year":2012,"count":7},{"year":2013,"count":4},{"year":2014,"count":6},{"year":2015,"count":3},{"year":2016,"count":5},{"year":2017,"count":4},{"year":2019,"count":2},{"year":2020,"count":2},{"year":2021,"count":6},{"year":2023,"count":1}],"oa_status":"closed","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fwnan.9","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/wnan.9","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/full-xml/10.1002/wnan.9","host_type":"publisher"},{"url":"https://wires.onlinelibrary.wiley.com/doi/pdf/10.1002/wnan.9","host_type":"publisher"},{"url":"https://doi.org/10.1002/wnan.9","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/20049799","host_type":"repository"}],"fields_of_study":["Coronary Interventions and Diagnostics","Protease and Inhibitor Mechanisms","Cardiomyopathy and Myosin Studies","Angiogenesis Inhibitors","Animals","Atherosclerosis","Diagnostic Imaging","Drug Carriers","Fluorocarbons","Humans","Molecular Probe Techniques","Nanoparticles"],"mesh_terms":["Animals","Diagnostic Imaging","Drug Carriers","Fluorocarbons","Humans","Molecular Probe Techniques","Angiogenesis Inhibitors","Atherosclerosis","Nanoparticles"],"keywords":["Targeted therapy","Targeted drug delivery","Molecular imaging","Drug delivery","Medicine","Proteomics","Drug","Nanotechnology","Pharmacology","Internal medicine","Biology","Cancer","In vivo","Materials science"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T22:02:35.530777Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}